NCT01628081

The Effect of Alga Dunaliella Bardawil on Psoriasis

A Randomized, Double-Blind, , Placebo Controlled, 18 Week Study To Evaluate the Efficacy of Adjuvant 9-cis-β-Carotene Rich Powder of the Alga Dunaliella Bardawil in Subjects With Plaque Type Psoriasis.

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Sheba Medical Center · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a double blind, parallel group, randomized study with 12 weeks of daily oral administration of Dunaliella or placebo in psoriasis patients.

Detailed description

Subjects will be screened for eligibility at the baseline visit for blood tests. After screen phase of maximum two weeks the subjects will be randomized to one of two treatments groups (1:1): Dunaliella or placebo. Each subject will have a final evaluation 4 weeks after the end of study drug treatment.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Alga Dunaliella Bardawil placebo	Dosage Regimen and Treatment Groups * Daily oral administration of: * Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening). * Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).
DIETARY_SUPPLEMENT	Dunaliella Bardawil	Dosage Regimen and Treatment Groups * Daily oral administration of: * Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening). * Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening).

Timeline

• Start date: 2012-06-01
• Primary completion: 2014-06-01
• Completion: 2014-07-01
• First posted: 2012-06-26
• Last updated: 2012-06-26

Locations

2 sites across 1 country: Israel